United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
United Therapeutics
Unlock to Claim this listing
Add / Modify Company
3.79
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Pharmaceutical ManufacturingESG/Ethical Impact
United Therapeutics is in the business of saving lives, and that is not limited to our focus on patients. We also put innovative efforts into mitigating our impact on the planet and prioritizing environmental stewardship. This focus has been a central part of our strategy for over a decade. Our commitment to social responsibility is rooted in our founding as a mission-driven company, intent on developing therapies, and one day a cure, for the rare, life-threatening lung condition known as pulmonary arterial hypertension (PAH). We strive to always operate with an eye toward corporate responsibility, environmental sustainability, and solid governance. These practices have long been embedded into our business at all levels. We have a strong tone at the top, with leaders who care deeply about improving the lives of patients, empowering our people, and making our planet and the communities in which we live and work better. We are guided by doing the right thing, while also relentlessly pushing to always do better. We also have an active, engaged, and diverse Board of Directors, which oversees our key business strategies and objectives, our risk management process, our compliance program, and key aspects of our corporate social responsibility program. We have dedicated teams to ensure that patients have access to our treatments. One team works with insurers to strive for the best possible coverage for our drugs, and we are proud of the results we have achieved. One of our strategic objectives is to achieve our goals by doing the right thing and using the highest ethical standards. This is evidenced by our commitment to a robust compliance program, ethical operations, scientific integrity, responsible sourcing, and environmental sustainability. Ethics is one of our core values, and we continue to enhance our programs across all of these areas. One important aspect of our approach to business ethics is a well-defined set of Compliance Principles that outlines how we behave, and clear leadership attributes that we expect from all Unitherians.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us

Awards Received
2023
Revenues
2204000000
Website Traffic
Employee Rating
3.8
Customer Rating
3.7
Company Size
100-1000
ESG Risk Rating
3